Li YR, et al. - In this study, researchers focused on the cardiovascular outcomes of linagliptin in patients with type 2 diabetes mellitus (T2DM) after acute coronary syndrome (ACS) or acute ischemic stroke (AIS). They found that in this patient population, treatment with linagliptin was not related to increased risks of cardiovascular death, non-fatal myocardial infarction, or non-fatal ischemic stroke.